Table 2.
Antitrypanosomal evaluation of the thiazole analogues in the STIB900 mouse model.
| Code | Dosage routeb | Dosage(4 × mg/kg) | Curesc | Survival (daysd) |
|---|---|---|---|---|
| 5a | ip | 5 | 1/4 | >44.5 |
| 6a | po | 25 | 0/4 | 35 |
| 7a | po | 25 | 0/4 | 41 |
| 5b | ip | 5 | 0/4 | 44.5 |
| 6b | po | 25 | 0/4 | 37.5 |
| 7b | po | 25 | 0/4 | 42.75 |
| 5c | ip | 5 | 0/4 | 30.25 |
| 6c | po | 25 | 0/4 | 24 |
| 7c | po | 25 | 0/4 | 35 |
| 5d | ip | 5 | 0/4 | >36 |
| 6d | po | 25 | 0/4 | 36.75 |
| 5e | ip | 5 | 0/4 | 50.5 |
| 6e | po | 25 | 1/4 | >37.5 |
| 7e | po | 25 | 1/4 | >47.25 |
| 5f | ip | 5 | 0/4 | 29.25 |
| 5g | ip | 5 | 0/4 | 21.5 |
| 6g | po | 25 | 0/4 | 9 |
| 7g | po | 25 | 0/4 | 9 |
| I | ip | 5 | 2/4 | .45 |
| IIa | ip | 5 | 1/4 | >46 |
| IIb | po | 25 5 |
4/4 0/4 |
>60 30 |
| IIc | ip | 5 | 3/4 | >54.5 |
| IId | po | 25 5 |
4/4 4/4 |
>60 >60 |
| IIe | ip | 5 | 2/4 | >48.75 |